Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes

Documenti analoghi

• Nephrology referral slows the progression of chronic kidney disease, especially among patients with anaemia, diabetes mellitus, or hypoalbuminemia: A single‐centre, retrospective cohort study
  di: Atsuki Ide, et al.
  Pubblicazione: (2024)
• A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
  di: Daniel Vincent O'Hara, et al.
  Pubblicazione: (2025)
• The sodium–glucose co‐transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor‐β
  di: Ting‐ting Lyu, et al.
  Pubblicazione: (2025)
• New Lower Bounds for C4-Free Subgraphs of the Hypercubes Q6, Q7, and Q8: Constructions, Structure, and Computational Method
  di: Minamoto, Minamo
  Pubblicazione: (2026)
• Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus
  di: SophieAnne Buckley, et al.
  Pubblicazione: (2024)